David D Thompson
Overview
Explore the profile of David D Thompson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
606
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Whyte M, Fujita K, Moseley S, Thompson D, McAlister W
J Bone Miner Res
. 2018 Jan;
33(5):868-874.
PMID: 29297597
Hypophosphatasia (HPP) is the heritable metabolic disease characterized by impaired skeletal mineralization due to low activity of the tissue-nonspecific isoenzyme of alkaline phosphatase. Although HPP during growth often manifests with...
2.
Whyte M, Madson K, Phillips D, Reeves A, McAlister W, Yakimoski A, et al.
JCI Insight
. 2016 Oct;
1(9):e85971.
PMID: 27699270
Hypophosphatasia (HPP) is caused by loss-of-function mutation(s) of the gene that encodes the tissue-nonspecific isoenzyme of alkaline phosphatase (TNSALP). Consequently, cell-surface deficiency of TNSALP phosphohydrolase activity leads to extracellular accumulation...
3.
Whyte M, Rockman-Greenberg C, Ozono K, Riese R, Moseley S, Melian A, et al.
J Clin Endocrinol Metab
. 2015 Nov;
101(1):334-42.
PMID: 26529632
Context: Hypophosphatasia (HPP) is an inborn error of metabolism that, in its most severe perinatal and infantile forms, results in 50-100% mortality, typically from respiratory complications. Objectives: Our objective was...
4.
Eastell R, Reid D, Vukicevic S, Ensrud K, LaCroix A, Thompson J, et al.
Bone
. 2012 Feb;
50(5):1135-40.
PMID: 22348983
The aims of this study were to describe the changes in bone turnover markers (BTMs) in response to lasofoxifene therapy; to describe the changes in BTMs in the individual; and...
5.
LaCroix A, Powles T, Osborne C, Wolter K, Thompson J, Thompson D, et al.
J Natl Cancer Inst
. 2010 Nov;
102(22):1706-15.
PMID: 21051656
Background: Currently available selective estrogen receptor modulators reduce the risk of breast cancer, but they are not widely used. In the Postmenopausal Evaluation and Risk-Reduction with Lasofoxifene (PEARL) trial, lasofoxifene...
6.
Ensrud K, Lacroix A, Thompson J, Thompson D, Eastell R, Reid D, et al.
Circulation
. 2010 Oct;
122(17):1716-24.
PMID: 20937977
Background: In the Postmenopausal Evaluation and Risk Reduction With Lasofoxifene (PEARL) trial, women assigned to lasofoxifene 0.5 mg/d had a lower risk of major coronary heart disease (CHD) events and...
7.
Cummings S, Ensrud K, Delmas P, LaCroix A, Vukicevic S, Reid D, et al.
N Engl J Med
. 2010 Feb;
362(8):686-96.
PMID: 20181970
Background: The effects of lasofoxifene on the risk of fractures, breast cancer, and cardiovascular disease are uncertain. Methods: In this randomized trial, we assigned 8556 women who were between the...
8.
Cameron K, Lefker B, Ke H, Li M, Zawistoski M, Tjoa C, et al.
Bioorg Med Chem Lett
. 2009 Mar;
19(7):2075-8.
PMID: 19250823
Sulfonamides, exemplified by 3a, were identified as highly selective EP(2) agonists. Lead optimization led to the identification of CP-533536, 7f, a potent and selective EP(2) agonist. CP-533536 demonstrated the ability...
9.
Wang X, Simmons H, Salatto C, Cosgrove P, Thompson D
Menopause
. 2006 Jul;
13(4):609-20.
PMID: 16837883
Objective: Lasofoxifene, a new selective estrogen-receptor modulator (SERM), shows efficacy in vaginal and vulvar atrophy in postmenopausal women. Here, we sought to explore the possible mechanisms of action for this...
10.
Ke H, Crawford D, Qi H, Simmons H, Owen T, Paralkar V, et al.
J Bone Miner Res
. 2006 Apr;
21(4):565-75.
PMID: 16598377
Unlabelled: CP432 is a newly discovered, nonprostanoid EP4 receptor selective prostaglandin E2 agonist. CP432 stimulates trabecular and cortical bone formation and restores bone mass and bone strength in aged ovariectomized...